Oncotelic JV Sapu starts registrational Phase 2b/3 trial of OT-101 in pancreatic cancer

Oncotelic Therapeutics, Inc.

Sapu Bioscience (Oncotelic 45% JV partner) signed master services agreement with Cromos Pharma for OT-101 registrational trial.
Trial: Phase 2b/3 of TGF-β2 antisense OT-101 + FOLFIRINOX vs FOLFIRINOX alone in advanced/metastatic pancreatic cancer.
Multinational trial targeting up to 500 patients across USA, EU, and China.
Oncotelic CEO states TGFβ2 suppression may more than double survival in pancreatic cancer.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.